The invention provides licB polypeptides and polynucleotides encoding licB polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing licB polypeptides to screen for antibacterial compounds.
Drawings
Claims18
An isolated protein comprising a polypeptide of SEQ ID NO:2.
An isolated protein comprising a polypeptide of at least 50 consecutive amino acids of SEQ ID NO:2.
An isolated protein comprising a polypeptide of at least 30 consecutive amino acids of SEQ ID NO:2.
17 Feb 2018Estimated · howhide20 years from earliest known nonprovisional domestic filing. Maintenance-fee lapses, terminal disclaimers and statutory extensions have not been checked. The continuity chain may be incomplete; this is not an enforceability determination. Patent term adjustment is unavailable; no adjustment was added.
USPTO file history isn’t available for this patent, so only indexed dates are shown.
Description14,646 words
Summary13,665 words
#This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their variants, agonists and antagonists, and their uses. In particular, the invention relates to novel polynucleotides and polypeptides of the licB family, hereinafter referred to as "licB".
#The Streptococci make up a medically important genera of microbes known to cause several types of disease in humans, including, for example, otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid. Since its isolation more than 100 years ago, Streptococcus pneumoniae has been one of the more intensively studied microbes. For example, much of our early understanding that DNA is, in fact, the genetic material was predicated on the work of Griffith and of Avery, Macleod and McCarty using this microbe. Despite the vast amount of research with S. pneumnoniae, many questions concerning the virulence of this microbe remain. It is particularly preferred to employ Streptococcal genes and gene products as targets for the development of antibiotics.
#The frequency of Streptococcus pneumoniae infections has risen dramatically in the past few decades. This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems. It is no longer uncommon to isolate Streptococcus pneumoniae strains which are resistant to some or all of the standard antibiotics. This phenomenon has created a demand for both new anti-microbial agents, vaccines, and diagnostic tests for this organism.
Detailed description981 words
#The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The examples are illustrative, but do not limit the invention.
#Strain Selection, Library Production and Sequencing
#The polynucleotide having a DNA sequence given in Table 1 SEQ ID NO:1 or 3! was obtained from a library of clones of chromosomal DNA of Streptococcus pneumoniae in E. coli. The sequencing data from two or more clones containing overlapping Streptococcus pneumoniae DNAs was used to construct the contiguous DNA sequence in SEQ ID NO:1. Libraries may be prepared by routine methods, for example, using Methods 1 and 2 below.